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Abstract Hormonal deficit in post-menopausal women has
been proposed to be one risk factor in Alzheimer's disease
(AD) since two thirds of AD patients are women. However,
large treatment trials showed negative effects of long-term
treatment with oestrogens in older women. Thus, oestrogen
treatment after menopause is still under debate, and several
hypotheses trying to explain the failure in outcome are under
discussion. Concurrently, it was shown that amyloid-beta
(Aβ) peptide, the main constituent of senile plaques, as well
as abnormally hyperphosphorylated tau protein, the main
component of neurofibrillary tangles, can modulate the level
of neurosteroids which notably represent neuroactive steroids
synthetized within the nervous system, independently of pe-
ripheral endocrine glands. In this review, we summarize the
role of neurosteroids especially that of oestrogen in AD and
discuss their potentially neuroprotective effects with specific
regard to the role of oestrogens on the maintenance and
function of mitochondria, important organelles which are
highly vulnerable to Aβ- and tau-induced toxicity. We also
discuss the role of Aβ-binding alcohol dehydrogenase
(ABAD), a mitochondrial enzyme able to bind Aβ peptide
thereby modifying mitochondrial function as well as oestra-
diol levels suggesting possible modes of interaction between
the three, and the potential therapeutic implication of inhibit-
ing Aβ–ABAD interaction.
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Introduction
Steroid hormones are molecules, mainly produced by endo-
crine glands such as the adrenal gland, gonads and placenta,
involved in the control of many physiological processes
mainly in the periphery, from reproductive behaviour to
stress response. In 1981, Baulieu and co-workers were the
first to demonstrate steroid production within the nervous
system itself [1]. They showed that the level of some ste-
roids, such as dehydroepiandrosterone (DHEA), was even
four times higher in the anterior brain of rats than in plasma
and nearly 18 times higher than in the posterior brain with
regard to its sulphated form (DHEAS). Of note, the level of
this steroid remained elevated in the brain even after adre-
nalectomy and castration. In the following decades, other
steroids were identified to be synthetized in situ in the brain,
and enzymatic activities of proteins involved in steroido-
genesis have been shown in many regions of the central and
peripheral nervous system, in neurons as well as in glial
cells [2–5]. Thus, this category of molecules is now called
“neurosteroids” and defines neuroactive steroids that are
synthetized within the nervous system, independently of
peripheral endocrine glands. While steroid hormones act at
a distance from their glands of origin in an endocrine way,
neurosteroids are synthetized by the nervous system and act
on the nervous system in an auto/paracrine configuration.
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Because of their lipophilic nature, peripheral steroid hor-
mones can freely cross cell membranes, including the
blood–brain barrier, and play an important role in the devel-
opment, maturation and differentiation of the central and
peripheral nervous system. However, since some steroids
are also synthetized within the nervous system, their blood
levels do not necessarily correspond to their brain concen-
trations [6]. Intra-cerebral steroid synthesis seems to play a
role in cognition, anxiety, depression, neuroprotection and
even nociception [7].
The ability to cross cellular membranes allows them to
act on nuclear receptors exhibiting genomic action by reg-
ulating gene transcription. This action seems to be important
during neonatal life where it has been shown that neuro-
steroids, such as progesterone (PROG) or oestradiol, are
able to promote dendritic growth, spinogenesis, synapto-
genesis and cell survival, particularly in the cerebellum
[5]. Some studies already demonstrated the role of neuro-
steroids, particularly oestrogens, in the regulation of glucose
homeostasis and lipid metabolism [8] as well as in neuro-
protection [9]. Risk for Alzheimer's disease (AD) is associ-
ated with age-related loss of sex steroid hormones in both
women and men [10, 11]. On the one hand, in post-
menopausal women, the precipitous depletion of oestrogens
and progestogens is hypothesized to increase susceptibility
to AD pathogenesis, a concept largely supported by epide-
miological evidence but refuted by some clinical findings,
above all, by results from the “Woman's health initiative
memory study” (WHIMS) (please see detailed discussion in
the “Conclusion” section). On the other hand, a growing
body of evidence indicates a more gradual age-related de-
cline in testosterone in men similarly associated with in-
creased risk to several diseases including AD. Since
testosterone is at least in part aromatized in the brain to
17β-oestradiol, a loss of it may also affect oestrogen-
mediated neuroprotective pathways. But also, the difference
between how rapidly and significantly the female versus
male primary sex hormones decline might partially contrib-
ute to higher AD incidences in women than in men [10].
Alzheimer's Disease, Oxidative Stress, Effect of Gender
and Neogenesis of Neurosteroids
AD is a neurodegenerative brain disorder and the most
common form of dementia among the elderly as shown by
the worldwide prevalence of the disease which was 26.6
million people in 2006 [12]. Clinical symptoms are charac-
terized by severe and progressive loss of memory, language
skills as well as spatial and temporal orientation. From a
cellular point of view, the pathological hallmark of AD is
the presence of extracellular senile plaques—composed of
aggregated amyloid-β peptide (Aβ)—and intracellular
neurofibrillary tangles (NFT)—consisting of aggregates of
abnormally hyperphosphorylated tau protein. A lot of efforts
have been made during the last years to understand the
pathogenesis of the disease, particularly the role of AD
key proteins, Aβ and tau, in oxidative stress and mitochon-
drial dysfunction [13].
Epidemiological and observational studies demonstrated
a higher prevalence and incidence of AD in women even
after adjusting for age—about two thirds of AD patients are
female—as well as a greater vulnerability to the disease
[14]. Thus, at early stages of neurofibrillary tangle develop-
ment, women exhibit greater senile plaque deposition than
men [15], and AD pathology is more strongly associated
with clinical dementia in female patients than in male [16].
The drop of oestrogen levels after menopause was proposed
to be one explanation to this phenomenon. However, there is
little information concerning changes of steroid levels in the
human brain during ageing and under dementia conditions.
As steroids present in nervous tissues originate from the
endocrine glands (steroid hormones) and from local synthe-
sis (neurosteroids), changes in blood levels of steroids with
age do not necessarily reflect changes in their brain levels.
The concentrations of a range of neurosteroids have recently
been measured in various brain regions of aged AD patients
and aged non-demented controls including both genders by
the very sensitive GC/MS methods [6]. Schumacher and
colleagues showed a general trend towards lower level of
steroids including oestrogen in AD patients compared to
controls. Notably, neurosteroid levels were negatively cor-
related with Aβ and phospho-tau in some brain regions [6].
Another study using radioimmunoassay for steroid quanti-
fication demonstrated a decrease in oestrogen level in post-
mortem brain from female AD patients aged 80 years and
older but no significant difference in the 60–79-year age
range compared to non-demented women [17]. However in
men, an age-dependent decrease of androgen level was
observed in the brain of non-demented subjects, which
was even more pronounced in the brain of male AD patients
[17]. Whereas large studies investigating systematically
gender differences with respect to Aβ and or tau pathology
in post-mortem brain tissue from AD patients are missing,
broad evidence emerged from transgenic mice models of
AD indicating an increased Aβ load burden and plaque
number in the female brain compared to age-matched male
mouse brain [11, 18]. Of note, consistent findings on greater
Aβ burden in females were found in different animal AD
models: Tg2576 (APPSWE) mice [19], APP/PS1 [20],
APP23 [21], as well as in triple transgenic mice, like
3xTg-AD mice [18, 22] and tripleAD mice ([23], with respect
to gender differences: unpublished observations). On the
basis that the estrous cycle in female mice is constantly
repeated until approximately 11 months of age and becomes
irregular between 12 and 14 months, the data demonstrating
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a significant enhancement of Aβ load in important brain
regions like the hippocampus from the female after the age
of 11 months are striking. Regarding tau pathology, no
gender differences have been observed in the latter triple
AD models. In agreement, NFT formation in Aβ-injected
tau transgenic mice (P301L) did not vary with gender [24].
Even though one single publication reported an enhanced
neurofibrillary pathology in female TAPP mice [25], all
together, these results point to the involvement of the Aβ
pathway, rather than the tau pathway, in the higher risk of
AD in women.
Interestingly, further supporting evidence comes from ox-
idative stress studies. Previous research of our group [26]
demonstrated a gender-specific partial up-regulation of anti-
oxidant defence in post-mortem brain regions from female
compared to male AD patients further indicating that oxida-
tive damage is caused rather by overproduction from reactive
oxygen species (ROS) than by insufficient detoxification of
ROS. Since mitochondria represent the major source of ROS,
the findings from Lloret and co-workers are of specific interest
showing that brain mitochondria from old female rats produce
higher levels of ROS after exposure to Aβ than age-matched
brain mitochondria from male rats [27].
A selection of studies attested neuroprotective effects of
neurosteroids against AD-related cellular and mitochondrial
injury, but the underlying mechanisms are still poorly
understood.
Findings of our group corroborated that AD key proteins
and oxidative stress are themselves able to modify neogenesis
of neurosteroids in a cellular AD model [28, 29] (Fig. 1). In
fact, treatment of human SH-SY5Y neuroblastoma cells with
H2O2 for 24 or 48 h led to a decrease of oestradiol synthesis.
This was paralleled by an increased cell death compared to
untreated controls and a down-regulation of the expression of
aromatase, an enzyme responsible for oestradiol formation
from testosterone. Interestingly, cell death was also observed
after inhibition of aromatase by treatment with letrozole,
suggesting that endogenous oestradiol formation plays a crit-
ical role in cell survival. Furthermore, if cells were pre-treated
with oestradiol, it was possible to protect them against H2O2
and letrozole-induced cell death. In agreement, a similar pro-
tective effect of oestradiol was observed in stress condition
experiments treating the same cell line with heavy metals,
such as cobalt and mercury [30].
In addition, modulation of neurosteroid production was
observed in SH-SY5Y cells overexpressing the human am-
yloid processor protein (APP) or human tau protein [28].
Indeed, overexpression of human wild-type Tau (hTau 40)
protein induced an increase in the production of PROG, 3α-
androstanediol and 17-hydroxyprogesterone, in contrast to
overexpression of the abnormally hyperphosphorylated tau
bearing the P301L mutation which led to a decrease in the
production of these neurosteroids. In parallel, a decrease of
PROG and 17-hydroxyprogesterone production was ob-
served in cells expressing human wild-type APP (wtAPP),
whereas 3α-androstanediol and oestradiol levels were in-
creased. These results provided first evidence that AD key
proteins are able to modulate, directly or indirectly, the
biological activity of the enzymatic machinery producing
neurosteroids. These findings were further confirmed by in
vitro experiments using native SH-SY5Y cells treated with
aggregated Aβ1-42 peptide for 24 h [31]. Since APPwt SH-
Fig. 1 Main biochemical pathways for neurosteroidogenesis in the ver-
tebrate brain. Boxes represent neurosteroids which are sensitive to modu-
lation by AD key proteins, Aβ and/or tau. Mitochondrial 17β-HSD
(marked by *) is equivalent to the ABAD in mitochondria. PREG preg-
nenolone, PROG progesterone, 17OH-PREG 17-hydroxypregnenolone,
17OH-PROG 17-hydroxyprogesterone, DHEA dehydroepiandrosterone,
DHP dihydroprogesterone, ALLOPREG allopregnanolone,DHT dihydro-
testosterone, P450scc cytochrome P450 cholesterol side chain cleavage,
P450c17 cytochrome P450c17, 3β-HSD 3β-hydroxysteroid dehydroge-
nase, 5α-R 5α-reductase, Arom. aromatase, 21-OHase 21-hydroxylase,
3α-HSOR 3α-hydroxysteroid oxydoreductase, 17β-HSD 17β-
hydroxysteroid dehydrogenase
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SY5Y cells secrete Aβ levels within nanomolar concentra-
tion range, treatment of native SH-SY5Y cells using a “non-
toxic” concentration range (100–1,000 nM, non-cell death-
inducing Aβ1-42 concentrations) revealed an increase in
oestradiol production, whereas toxic Aβ1–42 concentrations
within the micromolar range, leading to cell death, strongly
reduced oestradiol levels.
Modulation of steroid production was also shown in
other cell lines, for example in oligodendrocytes, where
DHEA production is up-regulated under oxidative stress
condition induced by treatment with Aβ peptide or Fe2+
[32]. Interestingly, similar results were found in Alzheimer
patients where DHEA was significantly elevated in brain
and cerebrospinal fluid when compared to control subjects
[33]. Finally, several reports propose the role of allopregna-
nolone (3α, 5α-THP) as a plasmatic biomarker for AD,
since it was shown that the level of this neurosteroid is
decreased by 25 % in the plasma of demented patients
compared with control subjects [34, 35].
The fact that the ability to produce neurosteroids is con-
served in the vertebrates' evolution suggests that this cate-
gory of molecules is important for living beings. Thus, we
could speculate that the modulation of their biosynthesis
plays an important role in the pathophysiology of neurode-
generative disorders, such as AD.
Neurosteroids, Especially Oestrogens,
and Neuroprotection in AD
Evidence of Neuroprotective Action of Steroids in Cellular
and Animal Studies
Neuroprotective effects of neurosteroids against a variety of
brain injuries have already been described for many years.
Numerous studies with the focus on oestrogens showed that
these molecules are able to enhance cerebral blood flow,
prevent atrophy of cholinergic neurons, and modulate the
effects of trophic factors in the brain [36]. Oestrogens are a
group of compounds known for their importance in the
estrous cycle including oestrone (E1), oestradiol (E2), and
oestriol (E3). Oestradiol is about ten times as potent as
oestrone and about 80 times as potent as oestriol in its
oestrogenic effect. Oestradiol is also present in males, being
produced as an active metabolic product of testosterone. The
serum levels of oestradiol in males (14–55 pg/mL) are
roughly comparable to those of post-menopausal women
(<35 pg/mL). Oestradiol in vivo is interconvertible with
oestrone, oestradiol to oestrone conversion being favoured;
however, evidence of metabolism is mainly derived from the
periphery.
Animal studies, especially in rodents and transgenic mice
models for AD, seem to confirm positive effects of oestrogen
treatment. It has been shown that a treatment with oestrogen in
mice expressing mutations in human APP (Swedish and Indi-
ana mutation) had an impact on APP processing decreasing
Aβ levels and so its aggregation into plaques [37]. Mecha-
nisms underlying this action of oestrogen are still poorly
understood, but as discussed by Pike et al. [11], it seems that
oestrogen amongst others is able to promote the α-secretase
pathway (non-amyloidogenic, meaning non-Aβ producing)
via activation of extracellular-regulated kinase 1 and 2 (ERK
1 and 2) and through the protein kinase C (PKC) signalling
pathway.
In triple transgenic AD mice, depletion in sex steroid
hormones induced by ovariectomy in adult females in-
creased significantly Aβ accumulation and had a negative
impact on cognitive performance [18, 38]. Treatment of
these ovariectomized mice with oestrogens was able to
prevent these effects vice versa. Of note, when PROG was
administrated in combination with oestrogens, the beneficial
effects on Aβ accumulation were blocked but not on cog-
nitive performance. However, oestrogen and PROG both
can modulate kinase and phosphatase activity involved in
tau phosphorylation, especially the glycogen synthase
kinase-3β (GSK-3β). Thus, oestrogen can induce the phos-
phorylation of GSK-3β which inactivates the enzyme and
reduces tau phosphorylation, whereas PROG can decrease
the expression of tau and GSK-3β [11, 39]. This suggests
that oestrogen and PROG not only can interact to regulate
APP processing and tau phosphorylation but can also act
independently on different AD pathways.
Cognitive effects of PROG were confirmed in mice bear-
ing the Swedish double mutation of APP and mutant pre-
seniline 1 (APPswe+PSEN1Δ9 mutant mice) which showed
decreased hippocampally mediated cognitive performances
compared to non-transgenic littermates [38]. In this AD
mouse model, PROG was able to improve the cognitive
performance in tasks involving the cortex but not in those
involving the hippocampus. Besides, APPswe+PSEN1Δ9
mice presented decreased 3α, 5α-THP levels (metabolite of
PROG) in the hippocampus, compared to wild-type mice,
suggesting that deficits in hippocampal function may be
due, at least in part, to reduced capacity to form 3α, 5α-
THP in the hippocampus. Furthermore, a more recent study
supported the role of 3α, 5α-THP in triple transgenic mice
model of AD (3xTgAD) by showing reduced Aβ generation
in the hippocampus, cortex and amygdala, coupled with an
increased cellular regeneration after treatment with 3α, 5α-
THP [40].
At the cellular level, oestrogen binds to nuclear receptors,
such as oestrogen receptor α and β (ER α/β), and acts as
transcription factor. It enhanced the expression of anti-
apoptotic proteins, such as Bcl-2 and Bcl-xL, and down-
regulated the expression of Bim, a pro-apoptotic factor,
preventing the initialisation of cell death programme by
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mitochondria [11, 41]. Another way that oestrogen can
protect cells from apoptosis is the activation of antioxidant
defence systems by up-regulating the expression of manga-
nese superoxide dismutase (MnSOD) and glutathione perox-
idase [42]. Thus, oestrogen can have direct antioxidant effects
by increasing reduced glutathione levels and decreasing oxi-
dative DNA damage in mitochondria, as observed in a study
using ovariectomized female rats [43]. Of note, oestrogen can
also modulate the redox state of cells by intervening with
several signalling pathways, such as mitogen-activated
protein kinase (MAPK), G protein-regulated signalling,
NFκB, c-fos, CREB, phosphatidylinositol-3-kinase, PKC
and Ca2+ influx [41, 44]. On the basis of this complex
mode of action, oestrogens not only seem to be able to
decrease oxidative stress markers, including lipid peroxi-
dation, protein oxidation and DNA damage, but can also
directly act on the regulation of mitochondrial function
[42].
Neurosteroids and Mitochondria: Focus on Potential
Protective Effects of Oestrogen Against Aβ-Induced
Toxicity
Mitochondria are the “powerhouses of the cell”, providing
the main part of cellular energy via ATP generation, which
is accomplished through oxidative phosphorylation from
nutritional sources [45]. They control cell survival and death
by regulating both energy metabolism and apoptotic path-
ways and contribute to many cellular functions, including
intracellular calcium homeostasis, alteration of the cellular
reduction–oxidation potential, cell cycle regulation and syn-
aptic plasticity [46]. Mitochondrial dysfunction has been
proposed as an underlying mechanism in the early stages
of AD [47, 48]. We recently summarized evidence from
ageing and Alzheimer models showing that the harmful trio
“ageing, Aβ and tau protein” triggers mitochondrial dys-
function through a number of pathways, such as impairment
of oxidative phosphorylation, elevation of reactive oxygen
species production and interaction with mitochondrial pro-
teins, contributing to the development and progression of
the disease [13, 49].
Mitochondria and neurosteroidogenesis are also closely
linked since mitochondria contain the first enzyme involved
in steroidogenesis, the cytochrome P450 cholesterol side
chain cleavage enzyme (P450scc) located at the inner side
of the mitochondrial membrane which is responsible for the
conversion of cholesterol to pregnenolone (PREG). The first
step of neurosteroidogenesis is the transfer of cholesterol
from the outer to the inner mitochondrial membrane. It is
also the rate-limiting step in the production of neurosteroids
because the ability of cholesterol to enter into mitochondria
to be available to the P450scc will determine the efficiency
of steroidogenesis [50]. Free cholesterol accumulates
outside of mitochondria and binds to the steroidogenic acute
regulatory protein, a hormone-induced mitochondria-
targeted protein that initiates cholesterol transfer into mito-
chondria. Then, molecules are transported inside mitochon-
dria by a protein complex including translocator proteins
(TSPO), a cholesterol-binding mitochondrial protein also
known under the name of peripheral-type benzodiazepine
receptor, which permits cholesterol transfer into mitochon-
dria and subsequent steroid formation.
It has been shown that TSPO is up-regulated in the post-
mortem brain of AD patients, resulting in an increased level
of PREG in the hippocampal region of those brains [50].
Interestingly, the level of 22R-hydroxycholesterol, a steroid
intermediate in the conversion of cholesterol to PREG, was
found at lower levels in the AD brain compared to the
control, which suggests that TSPO does not function nor-
mally in Alzheimer patients [33, 51].
From an energetic point of view, it is known that steroids
such as oestrogen can regulate mitochondrial metabolism by
increasing the expression of glucose transporter subunits
and by regulating some enzymes involved in the tricarbox-
ylic acid cycle (TCA cycle) as well as glycolysis, such as the
hexokinase, phosphofructokinase, pyruvate and malate de-
hydrogenase [41, 52], which leads to improved glucose
utilization by cells [11, 44] (Fig. 2).
Oestrogens seem to be able to up-regulate genes coding
for some electron transport chain components present in
nuclear and in mitochondrial DNA [53, 54]. In fact, an
oestrogen-induced increased expression of some subunits
of mitochondrial complex I (CI), cytochrome c oxidase
(complex IV or CIV) and F1 subunit of ATP synthase was
observed [41, 42, 52]. Furthermore, treatment of ovariecto-
mized female rats with oestradiol induced an increase of
mitochondrial respiratory function in the brain with regard
to an enhancement of O2 consumption coupled to an in-
creased activity of cytochrome c oxidase [53]. Thus, oes-
trogen seems to enhance the general metabolism in cells, but
besides, it seems also able to directly protect mitochondria
against oxidative stress-induced injury [52]. Thus, incuba-
tion of isolated mitochondria from the rat brain with oestra-
diol leads to a decrease of H2O2 production by this organelle
coupled with an increase of the mitochondrial membrane
potential (MMP). Furthermore, it has been proposed that its
phenolic A ring could allow oestradiol to intercalate into the
mitochondrial membrane and to avoid lipid peroxidation
occurring in stress condition [54], which could be responsi-
ble for the stabilization of the MMP. Moreover, oestradiol
seems to prevent the release of cytochrome c by mitochon-
dria (a mechanism known to induce apoptosis of cells by
activating the caspase cascade in the cytoplasm), a mecha-
nism increasing the efficiency of the respiratory chain [52].
Finally, another oestrogen signalling pathway avoiding
the negative effects of oxidative stress is the one regulating
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calcium homeostasis by inducing mitochondrial sequestra-
tion of cytosolic calcium [42, 54]. In fact, an imbalance of
calcium regulation can lead to an increase of ROS produc-
tion by activating the enzyme nitric oxide synthase, which
can in turn sensitize neural cells to oxidative damage. It has
been shown that an oestradiol treatment of primary hippo-
campal neurons was able to potentiate glutamatergic re-
sponse via NMDA receptor which resulted in an increased
influx of calcium in cells. This effect was coupled to an
induction of mitochondrial sequestration of cytosolic calci-
um and an increase of the mitochondrial calcium load tol-
erability thereby avoiding calcium-induced excitotoxicity as
well as promoting cell survival.
Taken together, all those different findings indicate that
oestrogen might be able to compensate deficits and injuries
that occur in AD, namely mitochondrial respiration impair-
ments, enhanced ROS production, excitotoxicity and, more
generally, metabolic deficits (Fig. 2). More recently, new light
has been shed on a mitochondrial enzyme that is able to
directly bind Aβ peptide and in which one of the main
substrate is 17β-oestradiol [55]. This enzyme is known under
the name of 17β-hydroxysteroid dehydrogenase type 10
(17β-HSD) or Aβ-binding alcohol dehydrogenase (ABAD).
ABAD, Oestradiol and Aβ-Induced Mitochondrial
Impairment
ABAD belongs to the alcohol dehydrogenase family, and it is
responsible for the reversible oxido/reduction of several sub-
strates including linear alcohols and steroids, such as 17β-
oestradiol, using NAD+ as cofactor [56]. Under normal con-
ditions (without Aβ), this enzyme plays a role in the regulation
of metabolic homeostasis, and its overexpression improved
cell viability and ATP content [57]. It has been shown that
ABAD is up-regulated in brains of AD mice as well as AD
patients [57, 58], and it has been suggested that the binding of
Aβ changes the conformation of the enzyme, which seems to
exacerbate mitochondrial dysfunction induced by Aβ.
Fig. 2 Modulation of mitochondrial function by Aβ, hyperphosphory-
lated tau and oestradiol. In AD, mitochondrial dysfunction was found
to be a central pathological mechanism which occurs already at early
stages of the disease. On one hand, studies showed that amyloid-β
peptide (Aβ) can be responsible of metabolic impairments, such as the
decrease of glucose consumption observed in the AD brain as well as
the calcium-induced excitotoxicity in neurons. It has been found that
hyperphosphorylated tau and Aβ are able to impair mitochondrial
respiration by inhibiting the ETC CI and CIV, respectively, inducing
decreased oxygen consumption, decreased ATP production and in-
creased ROS level. This oxidative stress induced by ETC dysfunction
can surpass cellular and mitochondrial scavenger (MnSOD, Cu/
ZnSOD) and impacts on MMP as well as mitochondrial DNA
(mtDNA). On the other hand, it has been shown that oestradiol can
increase glucose utilization by cells as well as ETC activity, stabilize
the MMP and prevent ROS production and calcium-induced excitotox-
icity. In the graph, E2 designates where oestradiol potentially acts on
mitochondria to compensate Aβ-induced toxicity. In turn, Aβ seems to
be able to impact oestradiol metabolism in mitochondria, since it can
be directly linked to the mitochondrial enzyme ABAD and possibly
modulates its enzymatic activity (such as the reversible conversion of
oestradiol to oestrone) and non-enzymatic activity (mitochondrial RN-
Ase P). ABAD Aβ-binding alcohol dehydrogenase, CI complex I, CII
complex II, CIII complex III, CIV complex IV, CV complex V, cyt c
cytochrome c, Cu/Zn SOD copper/zinc superoxide dismutase, MnSOD
manganese superoxide dismutase, TCA tricyclic acid, E2 oestradiol,
ROS reactive oxygen species, mtDNA mitochondrial DNA, ER oestro-
gen receptor
156 Mol Neurobiol (2012) 46:151–160
More recently, studies performed in transgenic micemodels
of AD showed that behavioural stress or depletion of ovarian
hormones by ovariectomy exacerbated mitochondrial dys-
function, aggravated plaque pathology and increased ABAD
expression in the brain [59, 60]. Furthermore, double trans-
genic mice overexpressing mutant APP and ABAD present an
earlier onset of cognitive impairment and histopathological
changes when compared to APP mice [49], suggesting that
Aβ–ABAD interaction is an important mechanism underlying
Aβ toxicity. This hypothesis is supported by a study from Yao
and collaborators who recently showed that inhibition of Aβ–
ABAD interaction by a decoy peptide can restore mitochon-
drial deficits (activity of mitochondrial respiratory complexes,
ROS level) and improve neuronal and cognitive function [60].
New interesting findings of our group seem to go in the
same way with regard to the use of a novel small ABAD-
specific compound inhibitor (AG18051) by investigating
the role of this enzyme in Aβ toxicity in human SH-SY5Y
cells treated for 5 days with Aβ1–42 0.5 uM [61]. The crystal
structure of human ABAD in presence of AG18051 showed
that the inhibitor formed a covalent link with the NAD+
cofactor and occupied the substrate-binding site of the en-
zyme [62]. Thus, the inhibitor was able to prevent Aβ-
induced cell death and significantly normalized metabolic
functions impaired by Aβ, such as cytosolic and mitochon-
drial ROS as well as mitochondrial respiration. Furthermore,
it was able to restore oestradiol levels which were reduced
after treatment with Aβ [31, 61]. What is interesting to note
is that the apparent protective effects of the ABAD inhibitor
seem to be independent on its interaction with Aβ. In fact, a
24-h pre-treatment with AG18051, before the incubation of
cells with Aβ1-42, was sufficient to prevent cell death, nor-
malize ROS production and restore mitochondrial respira-
tion. Regarding oestradiol level, we previously showed that
it decreased in the cytosol and increased in isolated mito-
chondria of SH-SY5Y cells after 5 days of treatment with
Aβ [49]. The ABAD inhibitor normalized the oestradiol
level in the cytosol [61], and preliminary data of our group
suggest a similar effect in isolated mitochondria (unpub-
lished data). Thus, we propose the following model of mode
of action: ABAD inhibitor is able to block Aβ toxicity by
changing ABAD configuration, which disables the binding
of Aβ thus preventing its toxic effects (Fig. 3). The action of
ABAD on the electron transport chain (ETC) is still unclear,
but the potential role of ABAD as mitochondrial RNAse P
directly links ABAD to the production of mitochondrial
ETC proteins and ROS generation [63]. Notably, AG18051
was able to normalize also this function of ABAD since
mitochondrial respiration was restored, but the underlying
mechanisms still remain unclear [61].
Thus, the interplay between ABAD, oestradiol and mito-
chondria may be a very interesting lead to follow in the
future to decode Aβ-induced mitochondrial toxicity and
explore therapeutic strategies of ABAD inhibition.
Conclusion
It is still debated whether oestrogen treatment after meno-
pause could result in improved cognitive function in wom-
en. This debate is based on many animal and cell culture
data showing that oestrogens can positively affect the ageing
and AD brain. It was recognized from former studies that
oestrogen depletion in post-menopausal women represents a
significant risk factor for the development of AD and that an
oestrogen replacement therapy may decrease this risk and
even delay disease progression [64, 65]. However, large
treatment trials showed negative effects of long-term
Fig. 3 Aβ, ABAD and mitochondria: modes of interactions. a Under
normal conditions, ABAD is responsible of the reversible oxido/reduc-
tion of linear alcohols and steroids, such as the reversible conversion
from oestradiol to oestrone. Its potential function as an RNAse P could
also be important for the good functioning of the mitochondrial ETC. b
Under AD-relevant pathological conditions, Aβ can directly bind the
mitochondrial enzyme ABAD, changing the configuration of the en-
zyme which seems to inhibit its activity and creates an imbalance
between oestradiol and oestrone. Aβ-induced ABAD misfolding can
impact ETC functioning and increase, directly or indirectly, ROS
production, which lead to cell death. c In the presence of AG18051
(AG), the binding of Aβ to ABAD is inhibited, normalizing oestradiol
level, ROS production, ETC activity, and improves cell survival.
ABAD Aβ-binding alcohol dehydrogenase, IMM inner mitochondrial
membrane, OMM outer mitochondrial membrane
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treatment with oestrogens in older women. Above all, results
from the WHIMS including 4,532 post-menopausal woman
aged over 68 years indicated a twofold increase in dementia
after 4.2 years of hormonal treatment (p.o. treatment with
premaxin plus medroxyprogesterone). In addition, the study
indicated potential risks for breast cancer, pulmonary embo-
lism and stroke [66, 67]. Some attribute this failure to the
synthetic nature of the hormones used in the WHIMS trial,
since in vitro studies support a beneficial role of oestradiol and
progesterone, but not of medroxyprogesterone used in the
WHIMS [68, 69]. Of note, medroxyprogesterone is not me-
tabolized to 3α, 5α-THP and can inhibit conversion of PROG
to 3α, 5α-THP [70]. Similarly, oestradiol, PROG or 3α, 5α-
THP, but not medroxyprogesterone, showed beneficial effects
in ageing, seizure, cortical contusion, ischaemia and diabetic
neuropathymodels [38]. Another theorywhich tries to explain
trial failure is the “critical window hypothesis”, asking for the
critical period where oestrogen might exert a neuroprotective
effect [71]. This hypothesis is substantiated by animal re-
search, e.g. mice which have undergone ovariectomy, but in
which oestrogen treatment was delayed substantially by
months (the equivalent of years in human terms), did not
benefit by this, as the animals did which received treatment
immediately after ovariectomy [72]. However, a recent meta-
analysis [73] indicated, contrary to expectations, that age of
women and duration of time relapsed when treatment was
initiated since menopause did not significantly affect treat-
ment outcome. Thus, natural oestradiol (E2) without a pro-
gestagen should represent the preferred treatment [73].
Furthermore, the oral route of drug delivery, being non-
invasive in nature, is by far the most convenient and preferred
route of administration in any acute or chronic treatment.
Though oestradiol itself from conventional oral oestradiol
formulations has the ability to cross the blood–brain barrier
(BBB) and reach the brain, but a large oral dose is required to
achieve therapeutic levels of oestradiol due to its non-
specificity for the brain. This non-specificity increases the
peripheral drug burden and subsequently potentiates the risk
of peripheral adverse effects. Furthermore, with specific re-
gard to the brain-specific action of oestradiol as a neuroste-
roid, independently of its action in the periphery, other modes
of administration (cyclical, nasal, polymer nanoparticles for
oral delivery) need to be sought and investigated [74]. Alter-
natively, the true potential of phyto-oestrogens, like the soy
isoflavones genistein, daidzein and glycitein, which activate
the same neuroprotective pathways than oestrogens but with
weak oestrogenic cellular effects that might be responsible for
the lower prevalence of AD in Japanese living in their ethnic
homeland compared to Japanese living in the USA [75], to
beneficially modify disease processes should be studied in
clinical trials [27]. In addition, the field could strongly benefit
from the successful development of oestrogen derivates that
have no unfavourable oestrogenic side effects. The successful
use of oestrogen or oestrogen-analogue therapies to delay,
prevent and/or treat AD will require additional research to
optimize key parameters of therapy.
In this context, the interplay between ABAD, oestradiol
and mitochondria and accordingly ABAD inhibition might
represent a further interesting lead to follow in the future.
Knowledge acquired from these studies will eventually be
applied to unravel the pathophysiology and to inform pre-
vention and intervention strategies of AD.
Acknowledgments This work has been supported by a grant from
the Swiss National Science Foundation (#31000_122572) and Synap-
sis Foundation.
Conflict of Interest The authors declare that they have no conflict of
interest.
Open Access This article is distributed under the terms of the Crea-
tive Commons Attribution License which permits any use, distribution,
and reproduction in any medium, provided the original author(s) and
the source are credited.
References
1. Corpechot C, Robel P, Axelson M, Sjovall J, Baulieu EE (1981)
Characterization and measurement of dehydroepiandrosterone sul-
fate in rat brain. Proc Natl Acad Sci USA 78(8):4704–4707
2. Mensah-Nyagan AG, Do-Rego JL, Beaujean D, Luu-The V, Pelletier
G, Vaudry H (1999) Neurosteroids: expression of steroidogenic
enzymes and regulation of steroid biosynthesis in the central nervous
system. Pharmacol Rev 51(1):63–81
3. Patte-Mensah C, Kibaly C, Boudard D, Schaeffer V, Begle A,
Saredi S, Meyer L, Mensah-Nyagan AG (2006) Neurogenic pain
and steroid synthesis in the spinal cord. J Mol Neurosci 28(1):17–
31. doi:10.1385/JMN:30:3:341
4. Plassart-Schiess E, Baulieu EE (2001) Neurosteroids: recent find-
ings. Brain Res Rev 37(1–3):133–140
5. Tsutsui K (2008) Neurosteroids in the Purkinje cell: biosynthesis, mode
of action and functional significance.Mol Neurobiol 37(2–3):116–125.
doi:10.1007/s12035-008-8024-1
6. Schumacher M, Weill-Engerer S, Liere P, Robert F, Franklin RJ,
Garcia-Segura LM, Lambert JJ, Mayo W, Melcangi RC, Parducz
A, Suter U, Carelli C, Baulieu EE, Akwa Y (2003) Steroid hor-
mones and neurosteroids in normal and pathological aging of the
nervous system. Prog Neurobiol 71(1):3–29
7. Mensah-Nyagan AG, Kibaly C, Schaeffer V, Venard C, Meyer L,
Patte-Mensah C (2008) Endogenous steroid production in the
spinal cord and potential involvement in neuropathic pain modu-
lation. J Steroid Biochem Mol Biol 109(3–5):286–293.
doi:10.1016/j.jsbmb.2008.03.002
8. Foryst-Ludwig A, Kintscher U (2010) Metabolic impact of estro-
gen signalling through ERalpha and ERbeta. J Steroid Biochem
Mol Biol 122(1–3):74–81. doi:10.1016/j.jsbmb.2010.06.012
9. Arnold S, Beyer C (2009) Neuroprotection by estrogen in the brain:
the mitochondrial compartment as presumed therapeutic target. J
Neurochem 110(1):1–11. doi:10.1111/j.1471-4159.2009.06133.x
10. Barron AM, Pike CJ (2012) Sex hormones, aging, and Alzheimer's
disease. Front Biosci (Elite Ed) 4:976–997
11. Pike CJ, Carroll JC, Rosario ER, Barron AM (2009) Protective
actions of sex steroid hormones in Alzheimer's disease. Front
Neuroendocrinol 30(2):239–258. doi:10.1016/j.yfrne.2009.04.015
158 Mol Neurobiol (2012) 46:151–160
12. Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM (2007)
Forecasting the global burden of Alzheimer's disease. Alzheimers
Dement 3(3):186–191. doi:10.1016/j.jalz.2007.04.381
13. Eckert A, Schmitt K, Gotz J (2011) Mitochondrial dysfunction—
the beginning of the end in Alzheimer's disease? Separate and
synergistic modes of tau and amyloid-beta toxicity. Alzheimers
Res Ther 3(2):15. doi:10.1186/alzrt74
14. Hy LX, Keller DM (2000) Prevalence of AD among whites: a
summary by levels of severity. Neurology 55(2):198–204
15. Corder EH, Ghebremedhin E, Taylor MG, Thal DR, Ohm TG,
Braak H (2004) The biphasic relationship between regional brain
senile plaque and neurofibrillary tangle distributions: modification
by age, sex, and APOE polymorphism. Ann N Y Acad Sci
1019:24–28. doi:10.1196/annals.1297
16. Barnes LL, Wilson RS, Bienias JL, Schneider JA, Evans DA,
Bennett DA (2005) Sex differences in the clinical manifestations
of Alzheimer disease pathology. Arch Gen Psychiatry 62(6):685–
691. doi:10.1001/archpsyc.62.6.685
17. Rosario ER, Chang L, Head EH, Stanczyk FZ, Pike CJ (2011)
Brain levels of sex steroid hormones in men and women during
normal aging and in Alzheimer's disease. Neurobiol Aging 32
(4):604–613. doi:10.1016/j.neurobiolaging.2009.04.008
18. Carroll JC, Rosario ER, Chang L, Stanczyk FZ, Oddo S, LaFerla
FM, Pike CJ (2007) Progesterone and estrogen regulate
Alzheimer-like neuropathology in female 3xTg-AD mice. J Neuro-
sci 27(48):13357–13365. doi:10.1523/JNEUROSCI.2718-07.2007
19. Callahan MJ, Lipinski WJ, Bian F, Durham RA, Pack A, Walker LC
(2001) Augmented senile plaque load in aged female beta-amyloid
precursor protein-transgenic mice. Am J Pathol 158(3):1173–1177
20. Wang J, Tanila H, Puolivali J, Kadish I, van Groen T (2003)
Gender differences in the amount and deposition of amyloidbeta
in APPswe and PS1 double transgenic mice. Neurobiol Dis 14
(3):318–327
21. Sturchler-Pierrat C, Staufenbiel M (2000) Pathogenic mechanisms
of Alzheimer's disease analyzed in the APP23 transgenic mouse
model. Ann N YAcad Sci 920:134–139
22. Hirata-Fukae C, Li HF, Hoe HS, Gray AJ, Minami SS, Hamada K,
Niikura T, Hua F, Tsukagoshi-Nagai H, Horikoshi-Sakuraba Y,
Mughal M, Rebeck GW, LaFerla FM, Mattson MP, Iwata N, Saido
TC, Klein WL, Duff KE, Aisen PS, Matsuoka Y (2008) Females
exhibit more extensive amyloid, but not tau, pathology in an
Alzheimer transgenic model. Brain Res 1216:92–103.
doi:10.1016/j.brainres.2008.03.079
23. Grueninger F, Bohrmann B, Czech C, Ballard TM, Frey JR,
Weidensteiner C, von Kienlin M, Ozmen L (2010) Phosphoryla-
tion of Tau at S422 is enhanced by Abeta in TauPS2APP triple
transgenic mice. Neurobiol Dis 37(2):294–306. doi:10.1016/
j.nbd.2009.09.004
24. Gotz J, Chen F, van Dorpe J, Nitsch RM (2001) Formation of
neurofibrillary tangles in P301l tau transgenic mice induced by Abeta
42 fibrils. Science 293(5534):1491–1495. doi:10.1126/science
25. Lewis J, Dickson DW, Lin WL, Chisholm L, Corral A, Jones G,
Yen SH, Sahara N, Skipper L, Yager D, Eckman C, Hardy J,
Hutton M, McGowan E (2001) Enhanced neurofibrillary degener-
ation in transgenic mice expressing mutant tau and APP. Science
293(5534):1487–1491. doi:10.1126/science.1058189
26. Schuessel K, Leutner S, Cairns NJ, Muller WE, Eckert A (2004)
Impact of gender on upregulation of antioxidant defence mecha-
nisms in Alzheimer's disease brain. J Neural Transm 111(9):1167–
1182. doi:10.1007/s00702-004-0156-5
27. Vina J, Lloret A (2010) Why women have more Alzheimer's
disease than men: gender and mitochondrial toxicity of amyloid-
beta peptide. J Alzheimers Dis 20(Suppl 2):S527–533.
doi:10.3233/JAD-2010-100501
28. Schaeffer V, Patte-Mensah C, Eckert A, Mensah-Nyagan AG (2006)
Modulation of neurosteroid production in human neuroblastoma
cells by Alzheimer's disease key proteins. J Neurobiol 66(8):868–
881. doi:10.1002/neu.20267
29. Schaeffer V, Patte-Mensah C, Eckert A, Mensah-Nyagan AG
(2008) Selective regulation of neurosteroid biosynthesis in human
neuroblastoma cells under hydrogen peroxide-induced oxidative
stress condition. Neuroscience 151(3):758–770. doi:10.1016/
j.neuroscience.2007.11.032
30. Olivieri G, Novakovic M, Savaskan E, Meier F, Baysang G,
Brockhaus M, Muller-Spahn F (2002) The effects of beta-
estradiol on SHSY5Y neuroblastoma cells during heavy metal
induced oxidative stress, neurotoxicity and beta-amyloid secretion.
Neuroscience 113(4):849–855
31. Schaeffer V, Meyer L, Patte-Mensah C, Eckert A, Mensah-Nyagan
AG (2008) Dose-dependent and sequence-sensitive effects of
amyloid-beta peptide on neurosteroidogenesis in human neuro-
blastoma cells. Neurochem Int 52(6):948–955. doi:10.1016/
j.neuint.2008.01.010
32. Brown RC, Cascio C, Papadopoulos V (2000) Pathways of neuro-
steroid biosynthesis in cell lines from human brain: regulation of
dehydroepiandrosterone formation by oxidative stress and beta-
amyloid peptide. J Neurochem 74(2):847–859
33. Brown RC, Han Z, Cascio C, Papadopoulos V (2003) Oxidative
stress-mediated DHEA formation in Alzheimer's disease patholo-
gy. Neurobiol Aging 24(1):57–65
34. Griffin LD, Gong W, Verot L, Mellon SH (2004) Niemann-Pick
type C disease involves disrupted neurosteroidogenesis and
responds to allopregnanolone. Nat Med 10(7):704–711.
doi:10.1038/nm1073
35. Smith CD, Wekstein DR, Markesbery WR, Frye CA (2006) 3alpha,
5alpha-THP: a potential plasma neurosteroid biomarker in Alzheimer's
disease and perhaps non-Alzheimer's dementia. Psychopharmacology
(Berl) 186(3):481–485. doi:10.1007/s00213-005-0186-1
36. Castellani RJ, Rolston RK, Smith MA (2010) Alzheimer disease.
Dis Mon 56(9):484–546. doi:10.1016/j.disamonth.2010.06.001
37. Amtul Z, Wang L, Westaway D, Rozmahel RF (2010) Neuro-
protective mechanism conferred by 17beta-estradiol on the bio-
chemical basis of Alzheimer's disease. Neuroscience 169(2):781–
786. doi:10.1016/j.neuroscience.2010.05.031
38. Frye CA, Walf AA (2008) Effects of progesterone administration
and APPswe+PSEN1Deltae9 mutation for cognitive performance
of mid-aged mice. Neurobiol Learn Mem 89(1):17–26.
doi:10.1016/j.nlm.2007.09.008
39. Goodenough S, Schleusner D, Pietrzik C, Skutella T, Behl C
(2005) Glycogen synthase kinase 3beta links neuroprotection by
17beta-estradiol to key Alzheimer processes. Neuroscience 132
(3):581–589. doi:10.1016/j.neuroscience.2004.12.029
40. Chen S, Wang JM, Irwin RW, Yao J, Liu L, Brinton RD (2011)
Allopregnanolone promotes regeneration and reduces beta-
amyloid burden in a preclinical model of Alzheimer's disease.
PLoS One 6(8):e24293. doi:10.1371/journal.pone.0024293
41. Simpkins JW, Yi KD, Yang SH, Dykens JA (2010) Mitochondrial
mechanisms of estrogen neuroprotection. Biochim Biophys Acta
1800(10):1113–1120. doi:10.1016/j.bbagen.2009.11.013
42. Nilsen J (2008) Estradiol and neurodegenerative oxidative stress.
Front Neuroendocr ino l 29(4) :463–475. doi :10.1016/
j.yfrne.2007.12.005
43. Borras C, Sastre J, Garcia-Sala D, Lloret A, Pallardo FV, Vina J
(2003) Mitochondria from females exhibit higher antioxidant gene
expression and lower oxidative damage than males. Free Radic
Biol Med 34(5):546–552
44. Brinton RD (2008) Estrogen regulation of glucose metabolism and
mitochondrial function: therapeutic implications for prevention of
Alzheimer's disease. Adv Drug Deliv Rev 60(13–14):1504–1511.
doi:10.1016/j.addr.2008.06.003
45. Scheffler IE (2001) A century of mitochondrial research: achieve-
ments and perspectives. Mitochondrion 1(1):3–31
Mol Neurobiol (2012) 46:151–160 159
46. Mattson MP, Gleichmann M, Cheng A (2008) Mitochondria in
neuroplasticity and neurological disorders. Neuron 60(5):748–766.
doi:10.1016/j.neuron.2008.10.010
47. Keil U, Bonert A, Marques CA, Scherping I, Weyermann J,
Strosznajder JB, Muller-Spahn F, Haass C, Czech C, Pradier L,
Muller WE, Eckert A (2004) Amyloid beta-induced changes in
nitric oxide production and mitochondrial activity lead to apopto-
sis. J Biol Chem 279(48):50310–50320. doi:10.1074/
jbc.M405600200
48. Leuner K, Schutt T, Kurz C, Eckert SH, Schiller C, Occhipinti A,
Mai S, Jendrach M, Eckert GP, Kruse SE, Palmiter RD, Brandt U,
Drose S, Wittig I, Willem M, Haass C, Reichert AS, Muller WE
(2012) Mitochondrion-derived reactive oxygen species lead to
enhanced amyloid beta formation. Antioxid Redox Signal 16
(12):1421–1433. doi:10.1089/ars.2011.4173
49. Schmitt K, Grimm A, Kazmierczak A, Strosznajder JB, Gotz J,
Eckert A (2011) Insights into mitochondrial dysfunction: aging
amyloid-beta and tau—a deleterious trio. Antioxid Redox Signal.
doi:10.1089/ars.2011.4400
50. Rone MB, Fan J, Papadopoulos V (2009) Cholesterol transport in
steroid biosynthesis: role of protein-protein interactions and impli-
cations in disease states. Biochim Biophys Acta 1791(7):646–658.
doi:10.1016/j.bbalip.2009.03.001
51. Papadopoulos V, Lecanu L, Brown RC, Han Z, Yao ZX (2006)
Peripheral-type benzodiazepine receptor in neurosteroid biosyn-
thesis, neuropathology and neurological disorders. Neuroscience
138(3):749–756. doi:10.1016/j.neuroscience.2005.05.063
52. Borras C, Gambini J, Lopez-Grueso R, Pallardo FV, Vina J (2010)
Direct antioxidant and protective effect of estradiol on isolated
mitochondria. Biochim Biophys Acta 1802(1):205–211.
doi:10.1016/j.bbadis.2009.09.007
53. Irwin RW, Yao J, Hamilton RT, Cadenas E, Brinton RD, Nilsen J
(2008) Progesterone and estrogen regulate oxidative metabolism in
brain mitochondria. Endocrinology 149(6):3167–3175.
doi:10.1210/en.2007-1227
54. Simpkins JW, Dykens JA (2008) Mitochondrial mechanisms of
estrogen neuroprotection. Brain Res Rev 57(2):421–430.
doi:10.1016/j.brainresrev.2007.04.007
55. Yan SD, Fu J, Soto C, Chen X, Zhu H, Al-Mohanna F, Collison K,
Zhu A, Stern E, Saido T, Tohyama M, Ogawa S, Roher A, Stern D
(1997) An intracellular protein that binds amyloid-beta peptide and
mediates neurotoxicity in Alzheimer's disease. Nature 389
(6652):689–695. doi:10.1038/39522
56. Yang SY, He XY, Schulz H (2005) Multiple functions of type 10
17beta-hydroxysteroid dehydrogenase. Trends Endocrinol Metab
16(4):167–175. doi:10.1016/j.tem.2005.03.006
57. Yan SD, Stern DM (2005) Mitochondrial dysfunction and Alz-
heimer's disease: role of amyloid-beta peptide alcohol dehydroge-
nase (ABAD). Int J Exp Pathol 86(3):161–171. doi:10.1111/
j.0959-9673.2005.00427.x
58. Kristofikova Z, Bockova M, Hegnerova K, Bartos A, Klaschka J,
Ricny J, Ripova D, Homola J (2009) Enhanced levels of mito-
chondrial enzyme 17beta-hydroxysteroid dehydrogenase type 10
in patients with Alzheimer disease and multiple sclerosis. Mol
Biosyst 5(10):1174–1179. doi:10.1039/b904799a
59. Seo JS, Lee KW, Kim TK, Baek IS, Im JY, Han PL (2011)
Behavioral stress causes mitochondrial dysfunction via ABAD
up-regulation and aggravates plaque pathology in the brain of a
mouse model of Alzheimer disease. Free Radic Biol Med 50
(11):1526–1535. doi:10.1016/j.freeradbiomed.2011.02.035
60. Yao J, Irwin R, Chen S, Hamilton R, Cadenas E, Brinton RD
(2011) Ovarian hormone loss induces bioenergetic deficits and
mitochondrial beta-amyloid. Neurobiol Aging. doi:10.1016/
j.neurobiolaging.2011.03.001
61. Lim YA, Grimm A, Giese M, Mensah-Nyagan AG, Villafranca JE,
Ittner LM, Eckert A, Gotz J (2011) Inhibition of the mitochondrial
enzyme ABAD restores the amyloid-beta-mediated deregulation of
estradiol. PLoS One 6(12):e28887. doi:10.1371/journal.pone.0028887
62. Kissinger CR, Rejto PA, Pelletier LA, Thomson JA, Showalter RE,
Abreo MA, Agree CS, Margosiak S, Meng JJ, Aust RM, Vanderpool
D, Li B, Tempczyk-Russell A, Villafranca JE (2004) Crystal structure
of human ABAD/HSD10 with a bound inhibitor: implications for
design of Alzheimer's disease therapeutics. J Mol Biol 342(3):943–
952. doi:10.1016/j.jmb.2004.07
63. Holzmann J, Rossmanith W (2009) tRNA recognition, processing,
and disease: hypotheses around an unorthodox type of RNase P in
human mitochondria. Mitochondrion 9(4):284–288. doi:10.1016/
j.mito.2009.03.008
64. Paganini-Hill A, Henderson VW (1996) Estrogen replacement
therapy and risk of Alzheimer disease. Arch Intern Med 156
(19):2213–2217
65. Tang MX, Jacobs D, Stern Y, Marder K, Schofield P, Gurland B,
Andrews H, Mayeux R (1996) Effect of oestrogen during meno-
pause on risk and age at onset of Alzheimer's disease. Lancet 348
(9025):429–432. doi:10.1016/S0140-6736(96)03356-9
66. Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA,
Black H, Bonds D, Brunner R, Brzyski R, Caan B, Chlebowski R,
Curb D, Gass M, Hays J, Heiss G, Hendrix S, Howard BV, Hsia J,
Hubbell A, Jackson R, Johnson KC, Judd H, Kotchen JM, Kuller
L, LaCroix AZ, Lane D, Langer RD, Lasser N, Lewis CE, Manson
J, Margolis K, Ockene J, O'Sullivan MJ, Phillips L, Prentice RL,
Ritenbaugh C, Robbins J, Rossouw JE, Sarto G, Stefanick ML,
Van Horn L, Wactawski-Wende J, Wallace R, Wassertheil-Smoller
S (2004) Effects of conjugated equine estrogen in postmenopausal
women with hysterectomy: the Women's Health Initiative random-
ized controlled trial. JAMA 291(14):1701–1712. doi:10.1001/
jama.291.14.1701
67. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg
C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson
KC, Kotchen JM, Ockene J (2002) Risks and benefits of estrogen
plus progestin in healthy postmenopausal women: principal results
from the Women's Health Initiative randomized controlled trial.
JAMA 288(3):321–333
68. Goodman Y, Bruce AJ, Cheng B, Mattson MP (1996) Estrogens
attenuate and corticosterone exacerbates excitotoxicity, oxidative
injury, and amyloid beta-peptide toxicity in hippocampal neurons.
J Neurochem 66(5):1836–1844
69. Nilsen J, Brinton RD (2002) Impact of progestins on estrogen-
induced neuroprotection: synergy by progesterone and 19-
norprogesterone and antagonism by medroxyprogesterone acetate.
Endocrinology 143(1):205–212
70. Penning TM, Sharp RB, Krieger NR (1985) Purification and
properties of 3 alpha-hydroxysteroid dehydrogenase from rat brain
cytosol. Inhibition by nonsteroidal anti-inflammatory drugs and
progestins. J Biol Chem 260(28):15266–15272
71. Henderson VW, Brinton RD (2010) Menopause and mitochondria:
windows into estrogen effects on Alzheimer's disease risk and
therapy. Prog Brain Res 182:77–96. doi:10.1016/S0079-6123(10)
82003-5
72. Gibbs RB (2010) Estrogen therapy and cognition: a review of the
cholinergic hypothesis. Endocr Rev 31(2):224–253. doi:10.1210/
er.2009-0036
73. Hogervorst E, Bandelow S (2010) Sex steroids to maintain cogni-
tive function in women after the menopause: a meta-analyses of
treatment trials. Maturitas 66(1):56–71. doi:10.1016/j.maturitas.
2010.02.005
74. Mittal G, Carswell H, Brett R, Currie S, Kumar MN (2011) Devel-
opment and evaluation of polymer nanoparticles for oral delivery of
estradiol to rat brain in a model of Alzheimer's pathology. J Control
Release 150(2):220–228. doi:10.1016/j.jconrel.2010.11.013
75. Grant WB (1999) Dietary links to Alzheimer's disease: 1999
update. J Alzheimers Dis 1(4–5):197–201
160 Mol Neurobiol (2012) 46:151–160
